跳转至内容
Merck
CN

A4978

Sigma-Aldrich

阿屈膦酸盐 钠 三水合物

≥97% (NMR), bone resorption inhibitor, powder

别名:

4-氨基-1-羟基-1-膦酸丁酯，单钠, MK-217

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C4H12NaNO7P2 · 3 H2O
化学文摘社编号:
121268-17-5
分子量:
325.12
MDL编号:
MFCD01748233
UNSPSC代码:
41106300
PubChem化学物质编号:
24724391
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

阿屈膦酸盐 钠 三水合物, ≥97% (NMR), powder

质量水平

100

方案

≥97% (NMR)

表单

powder

颜色

white

溶解性

water, double-distilled: 10 mg/mL

储存温度

−20°C

SMILES字符串

[Na+].[H]O[H].[H]O[H].[H]O[H].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O

InChI

1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1

InChI key

DCSBSVSZJRSITC-UHFFFAOYSA-M

基因信息

human ... FDPS(2224)

正在寻找类似产品? 访问 产品对比指南

相关类别

应用

阿仑膦酸钠三水合物已被用于：
  • 钛植入物的磷酸钙纳米颗粒（nCaP）二膦酸盐（BP）涂层并用于分析其成骨能力
  • 从老年骨质疏松症患者和健康人群中分离的人骨髓基质细胞（hBMSC）的成骨分化
  • 处理成骨细胞祖细胞和成骨细胞并通过传统测定和简单的数字图象分析研究其对成骨细胞行为的影响

    • 生化/生理作用

    阿仑膦酸钠三水合物是一种骨吸收抑制剂；法尼基二磷酸合成酶抑制剂 (IC 50 = 460 nM)；CD45 蛋白酪氨酸磷酸酶抑制剂。
    阿伦膦酸盐是一种含氮二膦酸盐，可阻断甲羟戊酸途径 并限制破骨功能和活性。阿仑膦酸钠三水合物是一种骨吸收抑制剂、法尼基二磷酸合成酶抑制剂和 CD45 蛋白酪氨酸磷酸酶抑制剂。

    制备说明

    重溶后，建议在-20°C下分装冻存。储备液在-20°C条件下可稳定保存6个月。

    象形图

    Exclamation mark
    GHS07

    警示用语：

    Warning

    危险声明

    H302

    危险分类

    Acute Tox. 4 Oral

    储存分类代码

    11 - Combustible Solids

    WGK

    WGK 3

    闪点(°F)

    Not applicable

    闪点(°C)

    Not applicable

    个人防护装备

    dust mask type N95 (US), Eyeshields, Gloves

    历史批次信息供参考:

    分析证书(COA)

    Lot/Batch Number
    0000392826
    0000341590
    0000341590
    0000392826
    0000159966

    没有发现合适的版本？

    如果您需要特殊版本，可通过批号或批次号查找具体证书。

    搜索COA

    已有该产品？

    在文件库中查找您最近购买产品的文档。

    访问文档库

    1. Which document(s) contains shelf-life or expiration date information for a given product?

      If available for a given product, the recommended re-test date or the expiration date can be found on the Certificate of Analysis.

    2. How do I get lot-specific information or a Certificate of Analysis?

      The lot specific COA document can be found by entering the lot number above under the "Documents" section.

    3. What quality control assays are typically done on Product A4978, Alendronate sodium trihydrate?

      The assays typically done on Product No. A4978 are appearance, solubility, elemental analysis for carbon, hydrogen and nitrogen (CHN) and proton NMR (1H-NMR) spectroscopy. The results of these assays may be found on the certificate of analysis for each lot.

    4. How should I dissolve Product A4978, Alendronate sodium trihydrate?

      This product is soluble in water at a concentration of 10 mg/mL.

    5. I see that Product A4978, Alendronate sodium trihydrate, is a trihydrate. How was the water content determined?

      Our supplier typically determines the water content by a loss on drying. We have not tested the water content in our labs here at Sigma by that method; we typically confirm the supplier’s value by CHN (elemental analysis for carbon, hydrogen and nitrogen, comparing the measured values to the theoretical values for the trihydrate).

    6. How do I find price and availability?

      There are several ways to find pricing and availability for our products. Once you log onto our website, you will find the price and availability displayed on the product detail page. You can contact any of our Customer Sales and Service offices to receive a quote.  USA customers:  1-800-325-3010 or view local office numbers.

    7. What is the Department of Transportation shipping information for this product?

      Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product. 

    8. My question is not addressed here, how can I contact Technical Service for assistance?

      Ask a Scientist here.

    Xuefeng Hu et al.
    Tissue engineering. Part A, 19(17-18), 1919-1930 (2013-04-02)
    Fibrous encapsulation can impair implant osseointegration and cause implant failure but currently there are limited strategies to address this problem. Since bisphosphonates (BPs), a class of drugs widely used to treat bone diseases, was recently found to induce fibroblast apoptosis
    Shmuel Banai et al.
    American heart journal, 165(2), 234-240 (2013-01-29)
    Activation of systemic innate immunity is critical in the chain of events leading to restenosis. LABR-312 is a novel compound that transiently modulates circulating monocytes, reducing accumulation of these cells at vascular injury sites and around stent struts. The purpose
    Mattias Ulmner et al.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(1), 76-82 (2013-09-03)
    To estimate the incidence of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) associated with the use of oral BPs and osteonecrosis of the jaw (ONJ) not associated with current or previous medication with a BP or radiotherapy to the head
    Robert Josse et al.
    Current medical research and opinion, 29(3), 205-216 (2013-01-10)
    According to the 2010 Osteoporosis Canada Clinical Practice Guidelines, denosumab is a first-line option for the pharmacological management of postmenopausal osteoporosis (PMO), along with several therapeutics that may be more familiar to family practice doctors: bisphosphonates, raloxifene, teriparatide, and hormone
    Núria Guañabens et al.
    Hepatology (Baltimore, Md.), 58(6), 2070-2078 (2013-05-21)
    Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC). Once-weekly alendronate improves bone mass and is well tolerated in these patients, but there is a concern because of poor compliance. Therefore, the efficacy, adherence
    查看所有相关文献

    商品

    Discover Bioactive Small Molecules for Lipid Signaling Research

    Discover Bioactive Small Molecules for Lipid Signaling Research

    我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

    联系客户支持